Profile: Di Wu, Ph.D.
Dr. Wu joined the Division of Clinical Pharmacology & Therapeutics as a Senior Research Associate in 2005. She has BS and MS in Pharmaceutical Analysis from China Pharmaceutical University and received her PhD in Natural Products Chemistry. She completed her postdoctoral training in Pharmaceutics in The Ohio State University. During the four-year postdoctoral program, she participated in pharmacology and drug discovery of non-steroidal selective androgen receptor modulators (SARMs), clinical development of new anticancer drugs, and discovery of new generations of oral drugs against leishmaniasis and trypanosomiasis. Her research was focused on pharmacokinetics and metabolism study on SARMs and sulfanilamide, clinical pharmacokinetics of flavopiridol as a breakthrough chemotherapeutic drug against chronic lymphocytic leukemia using modeling and simulation strategies, structure-activity relationship on SARMs, pharmacology and pharmacodynamics study on evaluating a non-steroidal SARM as a treatment for osteoporosis in rats, and methodology study on optimization of ionization efficiency for small-molecule compounds under soft ionization conditions in LC/MS/MS.
Dr. Wu's research at the Children's Hospital of Philadelphia is focused on incorporating preclinical and clinical knowledge to conduct researches in the area of translational medicine and therapeutics. Dr. Wu is working closely with Dr. Barrett in the development of pharmacometric approaches to advance PK-PD, novel biomarker development and disease progression modeling. Dr. Wu is also cooperating with Dr. Wade to optimize the care of critically ill newborns by providing rigorous pharmacokinetic (PK) and pharmacodynamic (PD) data to guide safe and effective drug therapy.